All clinical trials on the European Union Clinical Trials Register (EUCTR) must report their results in the registry within a year of completion. This site tracks who's doing this and who isn't. Learn more »
These trials completed more than 12 months ago and should have reported results. Some have, some have not.
These trials are not yet due to report results: some are ongoing, some completed within the past 12 months.
These trials have problematic data on the registry. Details why »
Status | Trial ID | Title | Completion date | Category |
---|---|---|---|---|
Reported results | 2006-001984-53 | Effectiveness of Dalteparin Therapy as Intervention in recurrent pregnancy loss | 2013-05-06 | due-trials |
Not reported | 2006-006957-29 | Influence of Duloxetin on C-fiber function and perception of deep somatic pain in major depression | 2009-09-03 | due-trials |
Not reported | 2006-006984-21 | prospective, randomized, open, multicentre trial to assess the influence of empiric antibiotic monotherapy with meropenem (Meronem) versus combination with moxifloxacin (Avalox) on the organ function ... | 2011-11-30 | due-trials |
Reported results | 2007-001548-36 | Nasale Inhalation von Pulmozyme bei Patienten mit Mukoviszidose und chronischer Rhinosinusitis mit dem Pari Sinus-Vernebler. - bizentrische, randomisierte, doppel-blinde, placebo-kontrollierte, prosp... | 2009-02-12 | due-trials |
Not reported | 2007-004333-42 | Prospective randomized clinical multicenter trial about the effect of an adjunctive intravenous treatment with sodium selenite (selenase®T, double-blind) and a procalcitonin guided causal therapy (ope... | 2014-11-30 | due-trials |
Completed, but no date, and reported results Terminated | 2008-000164-17 | Nasale Inhalation von Tobramycin mit dem Pari Sinus-Vernebler bei Patienten mit Mukoviszidose und Pseudomonasnachweis im Nasen-Nasennebenhöhlenbereich. Nasal inhalation of tobramycin by the Pari Sin... | bad-data | |
Reported results | 2008-007877-19 | Nasale Inhalation von Colistin mit dem Pari-Sinus-Vernebler bei Patienten mit Mukoviszidose und Pseudomonasnachweis im Nasen-Nasennebenhöhlenbereich. Nasal inhalation of colistin by the Pari Sinus ne... | 2012-04-19 | due-trials |
Exempt | 2009-011902-41 | Split-dose TPF-Induction chemotherapy before Surgery of Oropharyngeal and cavity of the mouth Cancer | 2016-01-13 | not-yet-due |
Ongoing | 2010-019688-12 | Prospective placebo controlled trial: Detection of coronary microembolization by Doppler ultrasound in patients with stable angina pectoris during percutaneous coronary interventions under an adjuncti... | not-yet-due | |
Not reported Terminated | 2010-022660-12 | A prospective, multi-center, randomized, double blinded, placebo-controlled study for the evaluation of Iloprost in the early postoperative period after liver transplantation | 2014-12-11 | due-trials |
Not reported | 2010-024262-22 | Treatment optimization of newly diagnosed Ph/BCR-ABL positive patients with chronic myeloid leukemia (CML) in chronic phase with nilotinib vs. nilotinib plus interferon alpha induction and nilotinib o... | 2022-05-31 | due-trials |
Completed, but no date Terminated | 2012-003023-38 | Phase II study of Bortezomib, Melphalan, Prednisone (VMP) followed by Lenalidomide maintenance vs. VMP without maintenance in Myeloma patients not eligible to high-dose chemotherapy and autologous ste... | bad-data | |
Not reported | 2014-004013-85 | Sequential versus simultaneous vaccination with pneumococcal conjugate vaccine (PCV13) and pneumococcal polysaccharide vaccine (PPV23) in unvaccinated older adults: Immunological memory and antibody l... | 2023-11-06 | due-trials |
Not reported | 2015-003502-16 | Treatment optimization for patients with chronic myeloid leukemia (CML) with treatment naïve disease (1st line) and patients with resistance or intolerance against alternative Abl-Kinase Inhibitors (≥... | 2023-03-31 | due-trials |
Reported results | 2016-000136-17 | Prospective, randomized, multicenter clinical trial on the impact of Therapeutic Drug Monitoring (TDM) of piperacillin on organ functions and survival in the treatment of severe sepsis or septic shock... | 2020-01-06 | due-trials |
Reported results Terminated | 2016-002388-33 | Therapeutic drug monitoring (TDM) for personalized antibiotic treatment with piperacillin-tazobactam (PipTaz) in patients with febrile neutropenia after myelo-suppressive cytostatic chemotherapy T... | 2018-06-10 | due-trials |
Reported results | 2016-004396-51 | Pentaerithrityl tetranitrate (PETN) for secondary prevention of intrauterine growth restriction (PETN Trial) Pentaeritrithyltetranitrat (PETN) zur Sekundärprophylaxe der intrauterinen Wachstumsret... | 2021-11-29 | due-trials |
Completed, but no date, and reported results Terminated | 2018-001874-89 | Randomised controlled multicentre study of albumin replacement therapy in septic shock Randomisierte kontrollierte multizentrische Studie zur Albuminersatztherapie im septischen Schock | bad-data | |
Other | 2018-002256-33 | Frontline Asciminib combination in chronic phase CML | not-yet-due | |
Reported results | 2018-003692-35 | Effects of empagliflozin on diuresis and renal function in patients with acute decompensated heart failure Auswirkungen von Empagliflozin auf Diurese und Nierenfunktion bei Patienten mit akuter dek... | 2021-06-29 | due-trials |
Completed, but no date Terminated | 2019-000136-26 | Midostaurin in MRD positive acute myeloid leukemia after allogeneic stem cell transplantation | bad-data | |
Not reported | 2019-001324-35 | Randomized single-blind study on the adherence to treatment with topical methylprednisolone aceponate (Advantan®) in different vehicles (AD-HERE) | 2022-07-19 | due-trials |
Not reported | 2020-001481-11 | Front line treatment with Ruxolitinib in stage II/III Covid-19 patients with defined Hyperinflammation | 2021-06-30 | due-trials |
Reported results | 2021-002098-25 | A randomized, controlled, multicenter, open label phase II clinical study to evaluate infliximab in the treatment of patients with severe COVID-19 disease (INFLIXCOVID) Eine randomisierte, kontro... | 2023-03-31 | due-trials |
Other | 2021-002300-12 | Epirubicin for the Treatment of Sepsis & Septic Shock Epirubicin für die Behandlung von Sepsis und septischen Schock | not-yet-due | |
Other | 2022-003069-39 | Venetoclax after TKI to target persisting stem cells in CML | not-yet-due |